SLU-PP-332 acts as a synthetic pan-agonist for estrogen-related receptors (ERRs) α, β, and γ, orphan nuclear receptors involved in energy metabolism regulation.
SLU-PP-332 and ERRα regulate genes involved in mitochondrial biogenesis. ERRα via PGC-1a, upregulates nuclear genes (like TFAM) that stimulate mitochondrial DNA replication and transcription. This will replenish the mitochondrial population and offset damaged ones.
ERRs are highly expressed in tissues with the highest energy demands, such as skeletal muscle, the heart, brain, kidneys, liver, and both white and brown adipose tissue.
Because these ERRs are so highly expressed in our highest energy demand tissues, this means that whenever you take SLU-PP-332, it’sdirectly fuelling the areas of our bodies that need it most, not only for fitness or training purposes, but for healthful living itself.
This is quite specifically why one of its many downstream effects is as a mitochondrial enhancer and exercise mimetic.
SLU-PP-332 binds to ERRs, particularly with higher potency at ERRα, enhancing their constitutive transcriptional activity without interacting with estrogen receptors.
SLU-PP-332 induces an acute aerobic exercise-like genetic program in skeletal muscle through ERRα-dependent mechanisms upon activation.
This leads to upregulation of ERR target genes encoding proteins for fatty acid oxidation, such as medium-chain acyl coenzyme A dehydrogenase.
SLU-PP-332 promotes mitochondrial biogenesis and enhances Krebs cycle activity, increasing oxidative metabolic capacity in high-energy tissues like muscle and liver.
It shifts whole-body fuel utilization toward lipids by decreasing the respiratory exchange ratio and boosting fatty acid oxidation by approximately 25%.
The compound increases glucose uptake and pyruvate levels in muscle while reducing glycogen content, mimicking exercise-induced metabolic flexibility.
SLU-PP-332 elevates resting energy expenditure without altering food intake or lean mass, reducing fat mass accumulation.
The liver decreases triglycerides and steatosis by enhancing lipid utilization, without significantly affecting gluconeogenic genes.
These molecular actions improve insulin sensitivity in obesity models by alleviating lipid-induced insulin resistance, positioning SLU-PP-332 as a potential therapeutic for metabolic disorders.
HED in research settings starting with 200mg/day, weekly increase to 400-600mg/day. Researchers observed significant weight loss effects in 6-7 weeks.
Related research materials:
→ SLU-PP-332 – Research-Grade Molecule for mitochondrial energy signaling
→ Glutathione (GSH) in redox balance and oxidative stress research